J. Craig
Venter, PhD, the pioneering biologist who led the first team to
sequence the human genome, received a State University of New York
honorary doctorate in science at a ceremony following the Sept. 20
grand opening of UB’s Clinical and Translational
Research Center.
President Satish K.
Tripathi called Venter—a former UB and Roswell Park Cancer
Institute scientist—“one of the 21st century's most
influential scientists and widely regarded as the world's foremost
leader in the field of genetic research.”
Venter developed a revolutionary strategy for rapid gene
discovery while working at the National Institutes of Health. He
went on to found the Institute for Genomic Research where, in 1995,
he and his team decoded the genome of the first free-living
organism.
At Celera Genomics, which he founded in 1998, Venter sequenced
the human genome using tools and techniques that he and his team
developed. The successful completion of this research culminated
with the February 2001 publication of the human genome in the
journal Science.
During his remarks, Venter expressed honest admiration for
UB’s newest research facility saying, “I'm actually
jealous,” he said. “This is some of the most beautiful
lab space I've seen.”
He also praised UB and Buffalo for committing to the creation of
a life sciences economy. “I'm a strong believer that the
future does rest in a bioeconomy.”
Venter gave an update on genomics, describing the massive
amounts of digital information that the research has produced and
the challenge caused by the “digitizing of
biology.”
Looking to the future, he said that personalized medicine based
on a patient's genetic information “will be a standard part
of medicine within a few years.”
Venter is founder and president of the J. Craig Venter
Institute, a not-for-profit, research and support organization
dedicated to human, microbial, plant and environmental genomic
research, the exploration of social and ethical issues in genomics,
and alternative energy solutions through genomics.
He and his team continue to blaze new trails in genomics
research and have published numerous important papers covering such
areas as the first complete diploid human genome, environmental
genomics and synthetic genomics.
He is also founder and chief executive officer of Synthetic
Genomics, a privately held company commercializing genomic
advances.